You are here

Home › Revive Therapeutics' experimental COVID treatment fails in late-stage study › Revive Therapeutics' experimental COVID treatment fails in late-stage study

Revive Therapeutics' experimental COVID treatment fails in late-stage study

Primary tabs

Revive Therapeutics' experimental COVID treatment fails in late-stage study

Thu, 2023-07-06 10:06 — mike kraft
Revive Therapeutics' experimental COVID treatment fails in late-stage study Canada-based Revive Therapeutics said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study. Reuters Reuters

...

The company was evaluating the safety and efficacy of its oral treatment, bucillamine, in the study which enrolled 713 patients with mild to moderate COVID-19.

...

Country / Region Tags: 
Canada
Global
General Topic Tags: 
COVID-19
Treatments
Public Health
Research
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
Medical - global
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks